We previously showed that cultured human umbilical vein endothelial cells (HEC) exposed to the inflammatory cytokines tumor necrosis factor- or interleukin-1 display increased activity of -galactoside 2,6-sialyltransferase. This is associated with enhanced expression of ligands for the B cell receptor CD22, which recognizes 2-6-linked sialic acids (Hanasaki, K., Varki, A., Stamenkovic, I., and Bevilacqua, M. P.(1994) J. Biol. Chem. 269, 10637-10643). Here we report that increased expression of CD22 ligands is a feature of dermal microvascular endothelial cells as well, and is also observed in response to the cytokine interleukin-4. Tumor necrosis factor- stimulation of HEC causes no change in the profile of endothelial glycoproteins recognized by CD22, but doubles the proportion of total cellular N-linked oligosaccharides capable of binding tightly to CD22. This modest change is sufficient to cause a marked increase in 2-6-linked sialic acid-dependent binding of Chinese hamster ovary (CHO) cells expressing recombinant human CD22. In contrast, B lymphoma cell lines expressing higher levels of cell surface CD22 do not show such sialic acid-dependent binding to activated HEC. Since B lymphoma cells themselves also express high levels of 2-6-linked sialic acids, their CD22 molecules might be rendered nonfunctional by endogenous ligands. In support of this, the lectin function of CD22 can be directly detected on transfected CHO cells, but not on B lymphoma cells. Furthermore, coexpression of -galactoside 2,6-sialyltransferase with CD22 in the CHO cells abrogates sialic acid-dependent binding to cytokine-activated HEC. However, such co-transfected cells can bind to B lymphoma cells in a manner apparently less dependent upon 2-6-linked sialic acid, suggesting CD22-mediated interactions that may not be directly dependent on its lectin function. Thus, CD22-mediated interactions between B cells and activated vascular endothelium may be positively regulated by induction of 2-6-linked sialic acid-bearing endothelial cell ligands, but negatively regulated by such ligands on the B cells expressing CD22. Since expression of both CD22 and -galactoside 2,6-sialyltransferase are regulated during B cell ontogeny, these findings could be of importance in B cell function and/or trafficking.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				N. Kimura, K. Ohmori, K. Miyazaki, M. Izawa, Y. Matsuzaki, Y. Yasuda, H. Takematsu, Y. Kozutsumi, A. Moriyama, and R. Kannagi Human B-lymphocytes Express {alpha}2-6-Sialylated 6-Sulfo-N-acetyllactosamine Serving as a Preferred Ligand for CD22/Siglec-2 J. Biol. Chem., November 2, 2007; 282(44): 32200 - 32207. [Abstract] [Full Text] [PDF]

				S. Ghosh, C. Bandulet, and L. Nitschke Regulation of B cell development and B cell signalling by CD22 and its ligands {alpha}2,6-linked sialic acids Int. Immunol., April 1, 2006; 18(4): 603 - 611. [Abstract] [Full Text] [PDF]

				A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF]

				J. J. Garcia-Vallejo, W. van Dijk, I. van Die, and S. I. Gringhuis Tumor Necrosis Factor-{alpha} Up-regulates the Expression of {beta}1,4-Galactosyltransferase I in Primary Human Endothelial Cells by mRNA Stabilization J. Biol. Chem., April 1, 2005; 280(13): 12676 - 12682. [Abstract] [Full Text] [PDF]

				M. Zhang and A. Varki Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis Glycobiology, November 1, 2004; 14(11): 939 - 949. [Abstract] [Full Text] [PDF]

				C.-P. Danzer, B. E. Collins, O. Blixt, J. C. Paulson, and L. Nitschke Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling Int. Immunol., October 1, 2003; 15(10): 1137 - 1147. [Abstract] [Full Text] [PDF]

				O. Blixt, B. E. Collins, I. M. van den Nieuwenhof, P. R. Crocker, and J. C. Paulson Sialoside Specificity of the Siglec Family Assessed Using Novel Multivalent Probes: IDENTIFICATION OF POTENT INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN J. Biol. Chem., August 15, 2003; 278(33): 31007 - 31019. [Abstract] [Full Text] [PDF]

				T. Angata and A. Varki Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily Glycobiology, April 1, 2000; 10(4): 431 - 438. [Abstract] [Full Text] [PDF]

				E. C. M. Brinkman-Van der Linden and A. Varki New Aspects of Siglec Binding Specificities, Including the Significance of Fucosylation and of the Sialyl-Tn Epitope J. Biol. Chem., March 17, 2000; 275(12): 8625 - 8632. [Abstract] [Full Text] [PDF]

				E. C. M. Brinkman-Van der Linden, E. R. Sjoberg, L. R. Juneja, P. R. Crocker, N. Varki, and A. Varki Loss of N-Glycolylneuraminic Acid in Human Evolution. IMPLICATIONS FOR SIALIC ACID RECOGNITION BY SIGLECS J. Biol. Chem., March 17, 2000; 275(12): 8633 - 8640. [Abstract] [Full Text] [PDF]

				G. Nicoll, J. Ni, D. Liu, P. Klenerman, J. Munday, S. Dubock, M.-G. Mattei, and P. R. Crocker Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and Monocytes J. Biol. Chem., November 26, 1999; 274(48): 34089 - 34095. [Abstract] [Full Text] [PDF]

				Y. Abe, C. W. Smith, J. P. Katkin, L. M. Thurmon, X. Xu, L. H. Mendoza, and C. M. Ballantyne Endothelial {alpha}2,6-Linked Sialic Acid Inhibits VCAM-1- Dependent Adhesion Under Flow Conditions J. Immunol., September 1, 1999; 163(5): 2867 - 2876. [Abstract] [Full Text] [PDF]

				L. Nitschke, H. Floyd, D. J.P. Ferguson, and P. R. Crocker Identification of CD22 Ligands on Bone Marrow Sinusoidal Endothelium Implicated in CD22-dependent Homing of Recirculating B Cells J. Exp. Med., May 3, 1999; 189(9): 1513 - 1518. [Abstract] [Full Text] [PDF]

				N. Razi and A. Varki Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes PNAS, June 23, 1998; 95(13): 7469 - 7474. [Abstract] [Full Text] [PDF]

				C. K. Liu, G. Wei, and W. J. Atwood Infection of Glial Cells by the Human Polyomavirus JC Is Mediated by an N-Linked Glycoprotein Containing Terminal alpha (2-6)-Linked Sialic Acids J. Virol., June 1, 1998; 72(6): 4643 - 4649. [Abstract] [Full Text] [PDF]

				T. Hennet, D. Chui, J. C. Paulson, and J. D. Marth Immune regulation by the ST6Gal sialyltransferase PNAS, April 14, 1998; 95(8): 4504 - 4509. [Abstract] [Full Text] [PDF]

				W.-X. Shi, R. Chammas, N. M. Varki, L. Powell, and A. Varki Sialic Acid 9-O-Acetylation on Murine Erythroleukemia Cells Affects Complement Activation, Binding to I-type Lectins, and Tissue Homing J. Biol. Chem., December 6, 1996; 271(49): 31526 - 31532. [Abstract] [Full Text] [PDF]

				D. Sgroi, A. Nocks, and I. Stamenkovic A Single N-linked Glycosylation Site Is Implicated in the Regulation of Ligand Recognition by the I-type Lectins CD22 and CD33 J. Biol. Chem., August 2, 1996; 271(31): 18803 - 18809. [Abstract] [Full Text] [PDF]

				W.-X. Shi, R. Chammas, and A. Varki Linkage-specific Action of Endogenous Sialic Acid O-Acetyltransferase in Chinese Hamster Ovary Cells J. Biol. Chem., June 21, 1996; 271(25): 15130 - 15138. [Abstract] [Full Text] [PDF]

				L. D. Powell and A. Varki I-type Lectins J. Biol. Chem., June 16, 1995; 270(24): 14243 - 14246. [Full Text] [PDF]

				L. D. Powell, R. K. Jain, S. Sabesan, and A. Varki Characterization of Sialyloligosaccharide Binding by Recombinant Soluble and Native Cell-associated CD22 J. Biol. Chem., March 31, 1995; 270(13): 7523 - 7532. [Abstract] [Full Text] [PDF]

				K. Hanasaki and A. Varki Binding of Human Plasma Sialoglycoproteins by the B Cell-specific Lectin CD22 J. Biol. Chem., March 31, 1995; 270(13): 7543 - 7550. [Abstract] [Full Text] [PDF]

				S. Kelm, J. Gerlach, R. Brossmer, C.-P. Danzer, and L. Nitschke The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound J. Exp. Med., May 6, 2002; 195(9): 1207 - 1213. [Abstract] [Full Text] [PDF]